Macrophage Chemokine Ligand 22 (CCL22) Competition ELISA Kit (MTS-1123-HM24)

It can, provided you validate dilution linearity and recovery. Competition ELISA sometimes tolerates complex matrices better because the readout is based on competitive binding rather than requiring simultaneous capture and detection on the target in the same way as sandwich assays. However, inhibitors or nonspecific binders can still affect antibody-antigen interactions. We recommend running a dilution series for each new matrix, including spike-and-recovery checks, and using matrix blanks. If your calculated concentrations are consistent across dilutions, that's strong evidence the matrix is not distorting the results.

Quantitation comes from disciplined curve usage and appropriate sample placement within the dynamic range. Always run a full standard curve on each plate, avoid extrapolating beyond the curve, and re-run samples that fall outside range with adjusted dilution. Use duplicates or triplicates, and include at least one internal control sample across plates for normalization. Because competition signal is inverse, prioritize calculated concentration and confidence intervals rather than comparing raw absorbance. Finally, document all incubation times and temperatures; competition assays are sensitive to subtle timing deviations.

Species-to-species comparison should be done cautiously. Antibody affinity may differ across orthologs or isoforms, affecting apparent concentration. The safest approach is to use a kit validated for the species you are testing and to avoid interpreting absolute values across different species assays as directly comparable. If you must compare, run species-specific standards and controls and interpret results as relative within each species context. For isoforms, confirm the antibody's epitope recognition; otherwise, your measurement may represent a subset of variants rather than total CCL22-like activity.